
1. antimicrob agents chemother. 2019 oct 22;63(11). pii: e02116-18. doi:
10.1128/aac.02116-18. print 2019 nov.

emergence plasmodium vivax resistance chloroquine french guiana.

musset l(#)(1), heugas c(#)(2)(3), naldjinan r(4), blanchet d(5), houze p(6),
abboud p(4), volney b(2), walter g(4), lazrek y(2), epelboin l(4), pelleau s(2), 
ringwald p(7), legrand e(8), demar m(4)(5), djossou f(9).

author information: 
(1)laboratoire de parasitologie, centre national de référence du paludisme, world
health organization collaborating center surveillance anti-malarial drug
resistance, institut pasteur de la guyane, cayenne, french guiana, france
lisemusset@gmail.com felix.djossou@ch-cayenne.fr.
(2)laboratoire de parasitologie, centre national de référence du paludisme, world
health organization collaborating center surveillance anti-malarial drug
resistance, institut pasteur de la guyane, cayenne, french guiana, france.
(3)faculty medicine, université de poitiers, poitiers, france.
(4)department infectious tropical diseases, centre hospitalier andrée
rosemon, cayenne, french guiana, france.
(5)laboratoire hospitalo-universitaire de parasitologie et mycologie, centre
hospitalier andrée rosemon, cayenne, french guiana, france.
(6)biochemistry laboratory, hôpital saint louis, paris, france.
(7)global malaria programme, world health organization, geneva, switzerland.
(8)malaria genetic resistance group, biology host-parasite interactions
unit, institut pasteur, paris, france.
(9)department infectious tropical diseases, centre hospitalier andrée
rosemon, cayenne, french guiana, france lisemusset@gmail.com
felix.djossou@ch-cayenne.fr.
(#)contributed equally

in south america, plasmodium vivax resistance chloroquine recently
reported brazil bolivia. objective study collect data
on chloroquine resistance french guiana associating retrospective
evaluation therapeutic efficacy analysis recurrent parasitemia from
any patients. patients p. vivax infection, confirmed microscopy a
body temperature ≥37.5°c, retrospectively identified cayenne hospital 
between 2009 2015. follow-up treatment responses performed according
to world health organization protocol. parasite resistance confirmed
after dosage plasma concentration chloroquine microsatellite
characterization. pvmdr1 pvcrt-o genes analyzed sequence and
gene copy number variation. among 172 patients followed 28 days, 164
presented adequate clinical parasitological responses. eight cases of
treatment failures identified (4.7%; n = 8/172), 14 days. the
therapeutic efficacy chloroquine estimated 95.3% (95% confidence
interval [ci], 92.5 98.1%; n = 164/172). among eight failures, five were
characterized: two cases true p. vivax chloroquine resistance (1.2%; 95% ci,
0 2.6%; n = 2/172), three cases found subtherapeutic
concentrations chloroquine. particular polymorphism plasmodium vivax
pvmdr1 pvcrt-o genes identified resistant parasites. this
identified level resistance p. vivax chloroquine french guiana does
not require change therapeutic recommendations. however, primaquine should
be administered frequently limit spread resistance, is
still need reliable molecular marker facilitate monitoring p.
vivax resistance chloroquine.

copyright © 2019 musset et al.

doi: 10.1128/aac.02116-18 
pmcid: pmc6811453
pmid: 31481442  [indexed medline]

